Gilead Stock Analysis: Buy Ahead Of The Upcoming Earnings (GILD)


  • Gilead Sciences has fallen over 6% since reaching an all time high on June 23rd.gilead stock analysis
  • The recent pullback is a great investing opportunity for long-term investors as concerns over HCV competition are overblown.
  • The valuation is very cheap, and the company is reducing its reliance on the HCV market.
  • I Know First Algorithm is bullish on Gilead Sciences in the long-term and believe it will reach new record highs.
Long-term investors should continue adding this stock at current prices. The recent pullback is a prime investing opportunity, as this stock is the most attractive option in not only the biotech sector, but quite possible of any stock on the market. The recent news that Harvoni was approved in Japan offers plenty of extra room for revenue growth, and the market in the US is far from drying out. Along with the new TFA drug trials for HIV patients and the potential for an acquisition to bolster its oncology offerings, there is plenty to be excited about moving forward.

Read The Full Article Here